表紙
市場調査レポート

ウロキナーゼの中国市場:2010年〜2019年

Investigation Report on China Urokinase Market 2010-2019

発行 China Research and Intelligence 商品コード 337515
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ウロキナーゼの中国市場:2010年〜2019年 Investigation Report on China Urokinase Market 2010-2019
出版日: 2015年08月18日 ページ情報: 英文 30 Pages
概要

2010年に1,820万人民元だった中国におけるウロキナーゼの売上は、その後12.30%のCAGRで拡大し、2014年には2,895万人民元に達し、その内の48.5%のシェアをNDPHARMが占めました。

当レポートでは、中国におけるウロキナーゼの特許および承認状況、売上・販売量の推移と予測、価格動向、主な製薬会社とその市場シェア、競合環境とその展望、主要メーカーのプロファイルなどを提供しています。

第1章 ウロキナーゼの関連概念

  • 適応
  • 世界市場における販売状況

第2章 中国におけるウロキナーゼの市場プロファイル

  • 特許・承認状況
  • 主要製薬会社
  • 市場規模

第3章 中国におけるウロキナーゼの販売状況

  • 販売額
    • 総販売額
    • 地域別の販売額
  • 販売量
    • 総販売量
    • 地域別の販売数

第4章 中国における主要ウロキナーゼメーカーの市場シェア

  • 販売額ベースの市場シェア
  • 販売量ベースの市場シェア

第5章 中国におけるウロキナーゼの剤形に関する調査

  • 剤形別の市場シェア:販売額ベース
  • 剤形別の市場シェア:販売量ベース

第6章 中国の病院におけるウロキナーゼの基準価格

  • Livzon Pharmaceutical Group Co., Ltd
  • NDPHARM
  • Tianjin Biochem Pharmaceutical Co., Ltd
  • PKU High-Tech Huatai Pharmaceutica
  • Liaoning Weixing Pharmaceutical Co., Ltd

第7章 中国市場におけるウロキナーゼの主要製薬会社

  • NDPHARM
  • Livzon Pharmaceutical Group Co., Ltd
  • Tianjin Biochem Pharmaceutical Co., Ltd
  • PKU High-Tech Huatai Pharmaceutica
  • Liaoning Weixing Pharmaceutical Co., Ltd

第8章 中国におけるウロキナーゼの市場見通し

  • 市場規模の予測
  • 競合情勢の予測
目次
Product Code: 1508298

As a serine protease, urokinase is isolated from human urine or cultivated in kidneys. And it consists of LMW-tcu-PA and HMW-tcu-PA.

Activation of urokinase triggers a proteolysis cascade that participates in thrombolysis degradation. Urokinase not only immediately removes clot but also enhances the activity of ADP enzyme so as to inhibit the platelet aggregation and prevent thrombolysis. Activity of plasmin is improved when urokinase is given in the form of intravenous drip and falls back to normal level several hours later. As a traditional thrombolytic drug, urokinase is widely used in treating such thrombotic diseases as acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombus and deep vein thrombosis.

With aging population and unreasonable eating habit, the incidence of thrombotic disease has gone up, which promotes the demand for urokinase. According to CRI's market survey, the annual sales value of urokinase rose from CNY 18.20 million in 2010 to CNY 28.95 million in 2014 with CAGR during this period reaching 12.30%. NDPHARM had the largest market share of about 48.5% for sales value in 2014.

The market size of urokinase is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of urokinase in China
  • competitive landscape of urokinase market in China
  • price of urokinase made by different enterprises in China
  • market outlook of urokinase in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antithrombotic agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Urokinase

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Urokinase in China

  • 2.1. Patent and Approval Information of Urokinase in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Urokinase Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Urokinase Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Urokinase in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Urokinase in Chinese Hospitals in 2014

  • 6.1. Livzon Pharmaceutical Group Co., Ltd
  • 6.2. NDPHARM
  • 6.3. Tianjin Biochem Pharmaceutical Co., Ltd
  • 6.4. PKU High-Tech Huatai Pharmaceutica
  • 6.5. Liaoning Weixing Pharmaceutical Co., Ltd

7. Major Manufacturers of Urokinase in Chinese Market, 2010-2014

  • 7.1. NDPHARM
  • 7.2. Livzon Pharmaceutical Group Co., Ltd
  • 7.3. Tianjin Biochem Pharmaceutical Co., Ltd
  • 7.4. PKU High-Tech Huatai Pharmaceutica
  • 7.5. Liaoning Weixing Pharmaceutical Co., Ltd

8. Market Outlook of Urokinase in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Information of Urokinase in China
  • Chart Approval Information of Urokinase in China
  • Chart Sales Status of Urokinase in China
  • Chart Sales Value of Urokinase in China, 2010-2014
  • Chart Sales Value of Urokinase in Some Regions in China, 2010-2014
  • Chart Sales Volume of Urokinase in China, 2010-2014
  • Chart Sales Volume of Urokinase in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Urokinase Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by NDPHARM in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Urokinase Made by Tianjin Biochem in China, 2010-2014
  • Chart Price of Urokinase Made by Livzon Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by NDPHARM in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by Tianjin Biochem Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by PKU High-Tech Huatai in Some Chinese Cities in 2014
  • Chart Price of Urokinase Made by Liaoning Weixing in Some Chinese Cities in 2014
Back to Top